Cardiology journal最新文献_第7页

Large-bore SOFIA catheter for bailout thrombus aspiration in STEMI. 大口径 SOFIA 导管用于抽吸 STEMI 中的救助血栓。

Cardiology journal Pub Date : 2024-01-01 DOI: 10.5603/cj.95375

Jacek Klaudel, Wojciech Trenkner, Krzysztof Pawłowski, Piotr Radowski, Dariusz Surman, Bartłomiej Ziniewicz, Michał Smolarczyk, Urszula Kossakowska-Jemioło, Włodzimierz Krasowski

引用次数: 0

Left atrial appendage thrombus in patients with atrial fibrillation who underwent oral anticoagulation. 口服抗凝治疗心房颤动患者左心房附件血栓的发生。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2022-06-15 DOI: 10.5603/CJ.a2022.0054

Jarosław Karwowski, Jerzy Rekosz, Renata Mączyńska-Mazuruk, Anna Wiktorska, Karol Wrzosek, Wioletta Loska, Katarzyna Szmarowska, Mateusz Solecki, Joanna Sumińska-Syska, Mirosław Dłużniewski

{"title":"Left atrial appendage thrombus in patients with atrial fibrillation who underwent oral anticoagulation.","authors":"Jarosław Karwowski, Jerzy Rekosz, Renata Mączyńska-Mazuruk, Anna Wiktorska, Karol Wrzosek, Wioletta Loska, Katarzyna Szmarowska, Mateusz Solecki, Joanna Sumińska-Syska, Mirosław Dłużniewski","doi":"10.5603/CJ.a2022.0054","DOIUrl":"10.5603/CJ.a2022.0054","url":null,"abstract":"Background: Electric cardioversion of atrial fibrillation (AF) is associated with an increased risk of embolism, with embolic material existing in the heart cavities. The initiation of oral anticoagulation therapy reduces the risk of thromboembolic events. The aims of this study were to evaluate the prevalence of left atrial appendage (LAA) thrombi in non-valvular AF, to compare vitamin K antagonists (VKAs) and non-vitamin K oral anticoagulants (NOACs) with respect to thrombus prevalence, and to evaluate the rate of LAA thrombus persistence on repeat transesophageal echocardiography (TEE) after treatment change.Methods: We enrolled 160 consecutive AF patients who presented with an AF duration > 48 h and had undergone TEE before cardioversion.Results: Left atrial appendage thrombus was observed in 12 (7.5%) patients, and spontaneous echo contrast 4 was observed in 19 (11.8%) patients; the incidence was similar between the NOAC and VKA groups (8.9% vs. 3.6% and 12.4% vs. 18.5 %, respectively). Among patients on NOAC, thrombus prevalence was detected in 8.4% of users of rivaroxaban, 8% of users of dabigatran, and 12.5% of users of apixaban.Conclusions: The LAA thrombus developed in 7.5% of patients despite anticoagulation therapy, demonstrating similar prevalence rates among patients either on NOAC or VKA. Lower mean LAA flow velocity and a history of vascular disease were independent predictors of embolic material in the LAA. It seems that in the case of embolic materials in LAA under NOAC treatment, switching to VKA provides additional clinical benefit to the patients.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46103594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The characteristic of acute coronary syndromes of patients with multivessel coronary artery disease in centers with and without cardiac surgery on-site. 在有和没有心脏外科现场的中心，多支血管冠状动脉疾病患者急性冠状动脉综合征的特征。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.5603/cj.95152

Krzysztof Brust, Karol Śmiech, Kamil Bujak, Tomasz Roleder, Mariusz Gąsior

{"title":"The characteristic of acute coronary syndromes of patients with multivessel coronary artery disease in centers with and without cardiac surgery on-site.","authors":"Krzysztof Brust, Karol Śmiech, Kamil Bujak, Tomasz Roleder, Mariusz Gąsior","doi":"10.5603/cj.95152","DOIUrl":"10.5603/cj.95152","url":null,"abstract":"Background: Multivessel disease (MVD) is diagnosed in a fair number of patients with acute coronary syndrome (ACS). There are 36 cardiac-surgery (CS) centres and 157 catheterization laboratories dedicated to treat ACS in Poland. The aim of the study was to analyze MVD patient outcomes presented with ACS in centers with or without CS on-site.Methods: The present study is a retrospective analysis (2017-2020) of MVD ACS patients (n = 4618) outcomes between those treated in centers with CS on site (n = 595) and those without CS (n = 4023).Results: Patients in CS centers had a higher prevalence of renal failure (13.3% vs. 8.8%, p ≤ 0.001) and a more frequent history of coronary angioplasty - percutaneous coronary intervention (18.9% vs. 14.4%, p = 0.005). During the coronary angiography a femoral artery access was more often used in CS center patients (47.1% vs. 15.2%, p < 0.001). Percutaneous coronary intervention of MVD was more often performed in CS centers (74.6% vs. 71.0%, p = 0.054). In-hospital death (7.6% vs. 4.6%, p = 0.002), reinfarction (1.1% vs. 0.1%, p < 0.001), hemorrhagic complications (6.4% vs. 1.6%, p < 0.001), recurrent target vessel revascularization (1.8% vs. 0.4%, p ≤ 0.001) and pulmonary edema (3.7% vs. 1.5%, p < 0.001) occurred more often in CS centers.Conclusions: The safety of ACS treatment in MVD patients in centers without CS on site is non-inferior to their treatment in centers with CS on site. Interestingly, there were more in-hospital adverse events observed in ACS MVD patients treated in centers with CS.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First use of the Impella 5.5 in a patient with cardiogenic shock to bridge to heart transplantation in Poland. 在波兰首次将 Impella 5.5 用于心源性休克患者，为心脏移植搭桥。

Cardiology journal Pub Date : 2024-01-01 DOI: 10.5603/cj.97518

Roman Przybylski, Mikołaj Błaziak, Maciej Bochenek, Anna Jarosz, Barbara Barteczko-Grajek, Michał Zakliczyński, Mateusz Sokolski, Mateusz Garus, Piotr Gajewski, Gracjan Iwanek, Tomasz Skalec, Krzysztof Reczuch, Wiktor Kuliczkowski

引用次数: 0

Coarctation of the aorta associated with anomalous origins of the coronary arteries. 伴有冠状动脉异常起源的主动脉共动脉瘤。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2024-09-10 DOI: 10.5603/cj.96025

Paweł Tyczyński, Szymon Kocańda, Daniel Płaczkiewicz, Justyna Gruczek, Maksymilian P Opolski, Elżbieta Czekajska, Adam Witkowski, Jacek Różański, Piotr Hoffman, Ilona Michałowska

引用次数: 0

Mediastinitis with aortic perforation after sternotomy. 胸骨切开术后纵隔炎伴主动脉穿孔。

Cardiology journal Pub Date : 2024-01-01 DOI: 10.5603/cj.99690

Sylwia Abramczuk, Ilona Michałowska, Adrianna Drynkowska, Sara Kochańska, Piotr Kołsut

引用次数: 0

Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations. 不同脂蛋白（a）浓度的急性冠状动脉综合征患者的长期双重抗血小板治疗。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2023-10-19 DOI: 10.5603/cj.93062

Kongyong Cui, Shaoyu Wu, Dong Yin, Weihua Song, Hongjian Wang, Chenggang Zhu, Lei Feng, Yuejin Yang, Rui Fu, Kefei Dou

{"title":"Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations.","authors":"Kongyong Cui, Shaoyu Wu, Dong Yin, Weihua Song, Hongjian Wang, Chenggang Zhu, Lei Feng, Yuejin Yang, Rui Fu, Kefei Dou","doi":"10.5603/cj.93062","DOIUrl":"10.5603/cj.93062","url":null,"abstract":"Background: Lipoprotein(a) [Lp(a)] was positively associated with recurrent ischemic events in patients with acute coronary syndrome (ACS). This study was performed to investigate the effect of Lp(a) levels on outcomes of dual antiplatelet therapy (DAPT) > 1 year versus DAPT ≤ 1 year after percutaneous coronary intervention (PCI) in this population.Methods: A total of 4,357 ACS patients who were event-free at 1 year after PCI were selected from the Fuwai PCI Registry, and patients were stratified into four groups according to DAPT duration (≤ 1 year vs. > 1 year) and Lp(a) levels (≤ 30 mg/dL vs. > 30 mg/dL). The primary endpoint was major adverse cardiovascular and cerebrovascular event (MACCE), defined as a composite of cardiac death, myocardial infarction or stroke.Results: After 2.4-year follow-up, the incidence of MACCE (HRadjusted 0.284, 95% CI 0.115-0.700; HRIPTW 0.351, 95% CI 0.164-0.751) were significantly reduced in DAPT > 1 year group than that in DAPT ≤ 1 year group in individuals with elevated Lp(a) levels. However, in individuals with normal Lp(a) levels, no statistically difference was found between these two groups in terms of MACCE, although the risks of all-cause death and definite/probable stent thrombosis were lower in DAPT > 1 year group. Notably, the risk of clinically relevant bleeding did not statistically differ between these two groups in individuals with different Lp(a) levels.Conclusions: This study firstly demonstrated that extended DAPT (> 1 year) was statistically associated with lower risk of ischemic events in ACS patients with elevated Lp(a) levels after PCI, whereas this association was not found in individuals with normal Lp(a) levels.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update. 高尿酸血症和高心血管风险患者的诊断和治疗专家共识。2023 年更新。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2023-12-29 DOI: 10.5603/cj.98254

Claudio Borghi, Justyna Domienik-Karłowicz, Andrzej Tykarski, Krzysztof J Filipiak, Milosz J Jaguszewski, Krzysztof Narkiewicz, Marcin Barylski, Artur Mamcarz, Jacek Wolf, Giuseppe Mancia

引用次数: 0

Acute eosinophilic myocarditis mimicking inferior myocardial infarction presenting with delayed hypereosinophilia. 模仿下心肌梗死的急性嗜酸性粒细胞性心肌炎出现延迟性高嗜酸性粒细胞血症。

Cardiology journal Pub Date : 2024-01-01 DOI: 10.5603/cj.96133

Takao Konishi, Naohiro Funayama, Daisuke Hotta, Shinya Tanaka

引用次数: 0

Quality of life and functioning in chronic disease - what to assess in heart failure patients. 慢性病患者的生活质量和功能--心力衰竭患者的评估内容。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2024-05-22 DOI: 10.5603/cj.97859

Aldona Kubica

引用次数: 0